RE: GEN1079 ready to dose?18 Jun 2026 14:52
There is no official corporate confirmation from Genmab or Scancell explicitly stating that GEN1079 is SC129. Neither company has publicly paired these two specific alphanumeric codes in their regulatory RNS announcements or SEC filings.Instead, the linkage relies entirely on circumstantial evidence, regulatory timelines, and clinical trial architecture noted by biotech analysts and investors:
1. Perfectly Aligned IND Timelines
The Genmab Action: In late 2025, Genmab submitted an Investigational New Drug (IND) application to the FDA for GEN1079.
The Scancell Action: Simultaneously, Scancell management announced in corporate presentations that preclinical development for their first out-licensed asset (SC129) was concluding, with an IND clearance pathway expected to transition the asset into the clinic near-term.
The Sequence: Genmab submitted two INDs at the exact same time (GEN1079 and GEN1106), which perfectly mirrors the fact that they hold exactly two licensed antibody programs from Scancell (SC129 and SC2811).
2. Matching Target Indications and Tumor Specificity
The strongest scientific evidence comes from comparing the clinical profile of GEN1079 on ClinicalTrials.gov (NCT07387068) with the known profile of SC129:SC129 is an anti-glycan antibody specifically generated to target sialyl-di-Lewis\({}^{a}\), which is highly over-expressed in gastrointestinal, pancreatic, and colorectal cancers.The Phase 1 protocol for GEN1079 strictly selects for advanced solid malignancies with a heavily explicit focus on those identical gastrointestinal and colorectal cohorts, requiring specific biomarker tissue collection to screen for matching target expression.
3. Financial Milestone Deadlines in Scancell's January 2026 Interim Results, directors explicitly guided the market to expect "milestones anticipated in 2026" originating specifically from Genmab. Genmab launched the Phase 1 infrastructure for GEN1079 in early 2026. The initiation of active patient screening for GEN1079 directly triggers the cash milestone window Scancell told investors to expect.
Summary of Status
Until Genmab publishes an updated, fully detailed clinical trial brochure naming sialyl-di-Lewis as the exact target for GEN1079, the relationship remains a highly probable correlation based on corporate footprints rather than a declared fact.
Sign In
Follow the stocks
